arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

PMV Pharmaceuticals, Inc.

PMVP

$1.37 ▼ -0.14 (-9.27%) at close

9 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

PMV Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $72.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -80.1% ↘

FCF / Share $-1.40 ↘

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-77.74M

↓ -32.4% —

FCF / Share Free cash flow per share

$-1.40

↓ -39.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	-29.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	20.8% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	10.6% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-25.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-32.4% Weak ↓ Weak Declining Year-over-year change in net income	14.9% Fair ↑ Fair Improving Year-over-year change in net income	5.9% Fair ↑ Fair Improving Year-over-year change in net income	-26.7% Weak ↑ Weak Improving Year-over-year change in net income	-68.0% Weak ↓ Weak Declining Year-over-year change in net income	-35.8% Weak Weak Year-over-year change in net income	-44.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-39.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	14.6% Fair ↑ Fair Improving Year-over-year change in free cash flow	25.1% Excellent Excellent Year-over-year change in free cash flow	-48.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	2.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	21.5% Fair ↑ Fair Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-80.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-38.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	37.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	41.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-74.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-31.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-25.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-74.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-595%)	-33.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-322%)	-30.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-304%)	-29.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-299%)	-18.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-225%)	-9.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-164%)	36.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+140%)	38.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+153%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-37.98M	$-40.88M	$-37.71M	$-108.30M	$-172.47M	$-361.42M	$-73.28M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-1.48	$-1.14	$-1.44	$-1.61	$-1.28	—	—	—	—
Free Cash Flow per Share (USD)	$-1.40	$-1.01	$-1.18	$-1.57	$-1.06	—	—	—	—
Book Value per Share (USD)	$1.96	$3.39	$4.39	$5.38	$6.79	$8.02	$-23.14	—	—
Tangible Book Value per Share (USD)	$1.96	$3.39	$4.39	$5.38	$6.79	$8.02	$-23.14	—	—
Basic Weighted Avg Shares (shares)	52.54M	51.58M	48.01M	45.59M	45.14M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$103.81M	$161.29M	$193.38M	$236.17M	$289.07M	$358.35M	$97.57M	—	—
Total Equity (USD)	$104.71M	$176.08M	$225.69M	$246.03M	$308.56M	$359.12M	$-70.47M	$-46.14M	$-29.73M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	$133.00K	$1.14M	$1.26M	$315.00K	$307.00K	$318.00K	$388.00K	$338.00K	—
Net Income, GAAP (USD)	$-77.74M	$-58.71M	$-68.96M	$-73.32M	$-57.85M	$-34.44M	$-25.35M	$-17.54M	—
Operating Cash Flow (USD)	$-73.58M	$-51.28M	$-55.66M	$-63.76M	$-46.57M	$-32.74M	$-22.07M	$-15.18M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 32 quarters

PMV Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PMVP with peers